BENGALURU, Nov 12 (Reuters) - Serum Institute of India, the world’s largest vaccine producer, said on Thursday it has made 40 million doses of AstraZeneca’s potential COVID-19 vaccine, and would soon begin making Novavax’s rival shot, as they both seek regulatory approval.
Serum said it has enrolled 1,600 participants in India for late-stage trials of AstraZeneca’s candidate, and also plans to seek regulatory approval to run late-stage trials for the Novavax vaccine.
The AstraZeneca vaccine, co-developed by Oxford University, is the most advanced in human testing in India, Serum said. (Reporting by Sachin Ravikumar; Editing by Tom Hogue)
Our Standards: The Thomson Reuters Trust Principles.